(Q37608311)

21 August 2017

1 reference

title

Virus-like particle vaccines and adjuvants: the HPV paradigm (English)

1 reference

21 August 2017

Luigi Buonaguro

3

0 references

Maria Lina Tornesello

object named as

Maria Lina Tornesello

series ordinal

2

0 references

author name string

Franco Maria Buonaguro

series ordinal

1

1 reference

21 August 2017

publication date

1 October 2009

1 reference

Expert Review of Vaccines

21 August 2017

published in

1 reference

21 August 2017

volume

8

1 reference

21 August 2017

issue

10

1 reference

21 August 2017

page(s)

1379-1398

1 reference

The physical characteristics of polyoma virus. I. Two types of particle

21 August 2017

cites work

1 reference

Mouse cellular DNA enclosed in polyoma viral capsids (pseudovirions).

21 January 2018

1 reference

Purification of polyoma virus

21 January 2018

1 reference

Self-assembly of purified polyomavirus capsid protein VP1.

21 January 2018

1 reference

Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

21 January 2018

1 reference

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

21 January 2018

1 reference

Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells

21 January 2018

1 reference

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

21 January 2018

1 reference

Nanoparticles target distinct dendritic cell populations according to their size

21 January 2018

1 reference

Characterization of an immediate splenic precursor of CD8+ dendritic cells capable of inducing antiviral T cell responses

21 January 2018

1 reference

Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies

21 January 2018

1 reference

Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques.

21 January 2018

1 reference

Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection

21 January 2018

1 reference

Packaging of small molecules into VP1-virus-like particles of the human polyomavirus JC virus

21 January 2018

1 reference

Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects

21 January 2018

1 reference

Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe

21 January 2018

1 reference

HPV6b virus like particles are potent immunogens without adjuvant in man.

21 January 2018

1 reference

A controlled trial of a human papillomavirus type 16 vaccine

21 January 2018

1 reference

Production of porcine parvovirus empty capsids with high immunogenic activity

21 January 2018

1 reference

Large scale production and downstream processing of a recombinant porcine parvovirus vaccine

21 January 2018

1 reference

Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses

21 January 2018

1 reference

Recombinant Norwalk virus-like particles given orally to volunteers: phase I study

21 January 2018

1 reference

Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein

21 January 2018

1 reference

Prospects for improved bluetongue vaccines

21 January 2018

1 reference

Development of baculovirus triple and quadruple expression vectors: co-expression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells.

21 January 2018

1 reference

Protective efficacy of virus-like particles for bluetongue disease

21 January 2018

1 reference

Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection.

21 January 2018

1 reference

Live attenuated bluetongue vaccine viruses in Dorset Poll sheep, before and after passage in vector midges (Diptera: Ceratopogonidae).

21 January 2018

1 reference

Nucleocapsid- and virus-like particles assemble in cells infected with recombinant baculoviruses or vaccinia viruses expressing the M and the S segments of Hantaan virus

21 January 2018

1 reference

Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system

21 January 2018

1 reference

Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins

21 January 2018

1 reference

Production and characterization of simian--human immunodeficiency virus-like particles

21 January 2018

1 reference

Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice

21 January 2018

1 reference

Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity

21 January 2018

1 reference

High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A.

21 January 2018

1 reference

Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles

21 January 2018

1 reference

DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.

21 January 2018

1 reference

Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP.

21 January 2018

1 reference

Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes

21 January 2018

1 reference

Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies

21 January 2018

1 reference

Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B.

21 January 2018

1 reference

Hepatitis B virus surface antigen (HBsAg) as carrier for synthetic peptides having an attached hydrophobic tail

21 January 2018

1 reference

Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles

21 January 2018

1 reference

Versatile RHDV virus-like particles: incorporation of antigens by genetic modification and chemical conjugation

21 January 2018

1 reference

Bacterial carriers and virus-like-particles as antigen delivery devices: role of dendritic cells in antigen presentation

21 January 2018

1 reference

Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells.

21 January 2018

1 reference

A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant

21 January 2018

1 reference

A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial

21 January 2018

1 reference

Perspectives: towards a peptide-based vaccine against hepatitis C virus.

21 January 2018

1 reference

Enhanced cytotoxicity of doxorubicin encapsulated in liposomes with reconstituted Sendai F-proteins

21 January 2018

1 reference

New technology platforms in the development of vaccines for the future

21 January 2018

1 reference

Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial

21 January 2018

1 reference

Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity.

21 January 2018

1 reference

A histidine switch in hemagglutinin-neuraminidase triggers paramyxovirus-cell membrane fusion

21 January 2018

1 reference

Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide

21 January 2018

1 reference

Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives

21 January 2018

1 reference

Aluminium compounds for use in vaccines

21 January 2018

1 reference

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

21 January 2018

1 reference

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers

21 January 2018

1 reference

Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin

21 January 2018

1 reference

A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant

21 January 2018

1 reference

Differential requirements for CTL generation by novel immunostimulants: APC tropism, use of the TAP-independent processing pathway, and dependency on CD80/CD86 costimulation

21 January 2018

1 reference

Liposome-mediated cytoplasmic delivery of proteins: an effective means of accessing the MHC class I-restricted antigen presentation pathway

21 January 2018

1 reference

Dendritic cells internalize vaccine adjuvant after intramuscular injection

21 January 2018

1 reference

Priming for virus-specific CD8+ but not CD4+ cytotoxic T lymphocytes with synthetic lipopeptide is influenced by acylation units and liposome encapsulation

21 January 2018

1 reference

Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2

21 January 2018

1 reference

Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design

21 January 2018

1 reference

The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis

21 January 2018

1 reference

High titers of circulating maternal antibodies suppress effector and memory B-cell responses induced by an attenuated rotavirus priming and rotavirus-like particle-immunostimulating complex boosting vaccine regimen

21 January 2018

1 reference

Immunobiology of the Tomatine adjuvant

21 January 2018

1 reference

Cooperation of Toll-like receptor signals in innate immune defence

21 January 2018

1 reference

Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides

21 January 2018

1 reference

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

21 January 2018

1 reference

CpG motifs in bacterial DNA trigger direct B-cell activation

21 January 2018

1 reference

A Toll-like receptor recognizes bacterial DNA

21 January 2018

1 reference

Toll-like receptors: critical proteins linking innate and acquired immunity

21 January 2018

1 reference

CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice

21 January 2018

1 reference

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

21 January 2018

1 reference

Formulation of vaccines containing CpG oligonucleotides and alum

21 January 2018

1 reference

Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo

21 January 2018

1 reference

Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide

21 January 2018

1 reference

Use of CpG oligodeoxynucleotides as immune adjuvants

21 January 2018

1 reference

Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.

21 January 2018

1 reference

Type I interferon-mediated stimulation of T cells by CpG DNA

21 January 2018

1 reference

Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine

21 January 2018

1 reference

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

21 January 2018

1 reference

Paracrine cytokine adjuvants in cancer immunotherapy

21 January 2018

1 reference

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

21 January 2018

1 reference

Cationic microparticles: A potent delivery system for DNA vaccines

21 January 2018

1 reference

Chitosan as a novel nasal delivery system for vaccines

21 January 2018

1 reference

Improving vaccine performance with adjuvants

21 January 2018

1 reference

Increased frequencies of CD4+ CD25(high) regulatory T cells in acute dengue infection

21 January 2018

1 reference

Antigen-independent memory CD8 T cells do not develop during chronic viral infection

21 January 2018

1 reference

Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice

21 January 2018

1 reference

Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response

21 January 2018

1 reference

Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics

21 January 2018

1 reference

Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease

21 January 2018

1 reference

Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease

21 January 2018

1 reference

Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

21 January 2018

1 reference

Molecular and cellular signatures of human vaccine adjuvants.

21 January 2018

1 reference

Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation

21 January 2018

1 reference

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia

21 January 2018

1 reference

Epidemiologic classification of human papillomavirus types associated with cervical cancer

21 January 2018

1 reference

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

21 January 2018

1 reference

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

21 January 2018

1 reference

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

21 January 2018

1 reference

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

21 January 2018

1 reference

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

21 January 2018

1 reference

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

21 January 2018

1 reference

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

21 January 2018

1 reference

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

21 January 2018

1 reference

Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials

21 January 2018

1 reference

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature

21 January 2018

1 reference

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

21 January 2018

1 reference

Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection

21 January 2018

1 reference

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials

21 January 2018

1 reference

Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.

21 January 2018

1 reference

High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts.

21 January 2018

1 reference

Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.

21 January 2018

1 reference

Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs.

21 January 2018

1 reference

Production of mink enteritis parvovirus empty capsids by expression in a baculovirus vector system: a recombinant vaccine for mink enteritis parvovirus in mink.

21 January 2018

1 reference

Characterization of a recombinant human calicivirus capsid protein expressed in mammalian cells

21 January 2018

1 reference

Characterization of capsid genes, expressed in the baculovirus system, of three new genetically distinct strains of "Norwalk-like viruses"

21 January 2018

1 reference

Human hepatitis B vaccine from recombinant yeast

21 January 2018

1 reference

Vaccinia virus recombinants co-expressing hepatitis B virus surface and core antigens

21 January 2018

1 reference

Characterization of virus-like particles produced by a recombinant baculovirus containing the gag gene of the bovine immunodeficiency-like virus

21 January 2018

1 reference

Analyses of the requirements for the synthesis of virus-like particles by feline immunodeficiency virus gag using baculovirus vectors

21 January 2018

1 reference

Expression of feline leukaemia virus gp85 and gag proteins and assembly into virus-like particles using the baculovirus expression vector system

21 January 2018

1 reference

PR domain of rous sarcoma virus Gag causes an assembly/budding defect in insect cells

21 January 2018

1 reference

Bovine leukemia virus Gag particle assembly in insect cells: formation of chimeric particles by domain-switched leukemia/lentivirus Gag polyprotein.

21 January 2018

1 reference

Immune response to recombinant visna virus Gag and Env precursor proteins synthesized in insect cells

21 January 2018

1 reference

Synthesis of Newcastle disease virus (NDV)-like envelopes in insect cells infected with a recombinant baculovirus expressing the haemagglutinin-neuraminidase of NDV.

21 January 2018

1 reference

Freeing vaccine adjuvants from dangerous immunological dogma

21 January 2018

1 reference

Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.09.81

1 reference

21 August 2017

1 reference